Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS-SAF302 intracerebral gene therapy study in mucopolysaccharidosis type IIIA
2018-000195-15Phase 2Completed
- Sponsor
- Lysogene
- Start
- Sep 2018
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Olenasufligene relduparvovec in mucopolysaccharidosis type III A, sponsored by Lysogene. Primary endpoint: Cognitive development quotient ratio at 24 months. Started Sep 2018; status: completed.
02
Drugs
Olenasufligene relduparvovec
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on 2018-000195-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000195-15.